GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.
Following this, the company will work with provincial and territorial governments and other stakeholders to make APRETUDE available through public drug plans.
Currently, GSK's stock is trading at $36.33, up 0.55 percent on the New York Stock Exchange.
For comments and feedback: editorial@rttnews.com